Endoscopic mucosal resection (EMR) for colorectal polyps is a safe and well-known procedure to prevent developing colorectal cancer.
Burden of health-care costs for patients with heparin replacement for colorectal EMR in Japan Endoscopic mucosal resection (EMR) for colorectal polyps is a safe and well-known procedure to prevent developing colorectal cancer.
There is, however, still higher risk of post-procedural bleeding (PPB) when patients take antithrombotic agents, especially taking dual antiplatelet therapy (DAPT) or anticoagulant. The Japanese guideline in 2012 recommends that warfarin or dabigatran should be replaced with unfractionated heparin for high-bleeding-risk endoscopic procedures in patients at high thrombotic risk. 1 Recently, there are some reports about adverse effects of heparin replacement therapy (HR), which increases the risk of PPB with a pooled odds ratio of 8 up to 17. [2] [3] [4] And furthermore, little has been reported yet about other disadvantages of HR such as longer hospital stays or costs of hospitalization and high incidence of PPB.
We therefore evaluated the clinical impacts of cost-balance of colorectal EMR between HR group and non-HR group in Japan.
We enrolled 59 consecutive patients who underwent colorectal EMR with HR at our institution between March 2015 and April 2016.
We evaluated the incidence of PPB, taking anticoagulants or antiplate- 
